InterMune Files NDA For IPF Drug Despite Mixed Pivotal Trial Results
This article was originally published in The Pink Sheet Daily
Executive Summary
With IPF currently an unmet medical need in the U.S.; company seeks priority review; drug marketed in Japan by partner Shionogi.
You may also be interested in...
InterMune's Pirfenidone Gets Advisory Committee Date; Panel Will Weigh Unmet Need Against Mixed Results
FDA has granted the drug priority review status due to the unmet medical need it addresses.
InterMune's Pirfenidone Gets Advisory Committee Date; Panel Will Weigh Unmet Need Against Mixed Results
FDA has granted the drug priority review status due to the unmet medical need it addresses.
China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone
SHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)